fda social media

50
PHARMA, THE FDA & SOCIAL MEDIA: Uncertainty Can Be A Guiding Light

Upload: brad-mccormick

Post on 01-Nov-2014

912 views

Category:

Health & Medicine


0 download

DESCRIPTION

"Uncertainty can be a Guiding Light" To truly leverage the power of social networks, Pharma need to understand the principle of open innovation and learn to live with (and take) communication risk. The FDA will never give crystal clear guidelines on social media. Their existing statements is all the real direction any compnay needs

TRANSCRIPT

Page 1: FDA Social Media

PHARMA, THE FDA & SOCIAL MEDIA:Uncertainty Can Be A Guiding Light

Page 2: FDA Social Media

“Uncertainty Can Be A Guiding Light”-U2, Zooropa 1993

Page 3: FDA Social Media

White Blood Cell Count: 50,000

Page 4: FDA Social Media

What I Will Address

• What the FDA has said, will likely say, and is not going to say.

• The business case for embracing uncertainty

• 6 Misconceptions for social media

• What this means for Canadian Pharma and Pharma overall

• Q&A

Page 5: FDA Social Media

First, 3 Facts:

Page 6: FDA Social Media

Fact #1:The World is Getting Older, Faster

10k x 365 x 19 years

Page 7: FDA Social Media

Fact #2:Traditional DTC Marketing Models are losing effectiveness

Page 8: FDA Social Media

Fact #3:The FDA has yet to issue anything since Part 15 hearings.

Page 9: FDA Social Media

FDA: what they have said, are going to say, and are not going to say

Page 10: FDA Social Media

FDA: What They Have Already

Said.

Page 11: FDA Social Media

“Follow the regulations”

Advise given by Tom Abrams, the head of FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC), regarding Pharma & Social Media Feb 2011

What They FDA Has Said

Page 12: FDA Social Media

1. Adverse Event information must be included in all DTC advertising materials.

2. Reports of Adverse Events must be reported if they meet 4 basic criteria.

3. Companies are required to ensure that adverse information is listed and is accurate on any site that is sponsored by the product manfactuer.

What the FDA Has Said:

Page 13: FDA Social Media

52 Warning Letters in

2010.

Page 14: FDA Social Media

SOURCE: Eye on FDA: http://www.eyeonfda.com/eye_on_fda/2011/01/ddmac-warning-and-nov-letters-lookback-for-2010.html

Page 15: FDA Social Media

SOURCE: Eye on FDA: http://www.eyeonfda.com/eye_on_fda/2011/01/ddmac-warning-and-nov-letters-lookback-for-2010.html

Page 16: FDA Social Media

Only Social Media Violation in 2010: Established Rule

Page 17: FDA Social Media

FDA: What They Are (Most

Likely) Going to Say.

Page 18: FDA Social Media

•What Constitutes a “Sponsored” site?

•Safe Harbor for correct information (i.e. Wikipedia)

• Safe Harbor for Adverse Events (does not have to monitor every single site)

• Possible clarity on “One Click” Rule

Low Hanging Fruit

Page 19: FDA Social Media

FDA: What They Are Not Going

to Say

Page 20: FDA Social Media

Do Not Expect 100% Clarity

The FDA will not "do guidance on specific technology platforms such as YouTube, Facebook, or Twitter …”

Tom Abrams, the Head of FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) , Feb 2011

Page 21: FDA Social Media

Do Not Expect 100% Clarity

“…DDMAC is unlikely to create a major new standard for social media…”

John KampDirector,Coalition for Healthcare Communication

Page 22: FDA Social Media

Do Not Expect 100% Clarity

“…It’s impossible to expect the FDA to offer direct guidance [on Pharma & Social Media]”

Peter PittsDirector of Global Regulatory, Porter NovelliFormer Deputy Commission, FDA

impossible?

Page 23: FDA Social Media

Do Not Expect 100% Clarity“The real question is whether Pharma has the will to engage, because they certainty have the ability if they choose to use it.”

Peter PittsDirector of Global Regulatory, Porter NovelliFormer Deputy Commission, FDA

Page 24: FDA Social Media

The Pharma Business Case for Embracing Uncertainty

Page 25: FDA Social Media

“In the age of Facebook and Google, it seems there should be a better, more systematic way of harnessing this communal wisdom and cultivating this sort of medical discovery. Enter open innovation.”

Page 26: FDA Social Media

Past: Closed Innovation Future: Open Innovation

Page 27: FDA Social Media

Chess:•Clear, specific, unchanging rules•Finite set of pieces•Finite Set of moves•Clear how investment can lead to victory•Largest dynamic is intellectual•No ambiguity

Page 28: FDA Social Media

Poker:•Few basic rules, but they can be modified•Finite set of pieces, infinite set of moves•Unclear how investment will lead to victory•Largest dynamic is social, emotional•Lots of Ambiguity. Lots of Risk.

Page 29: FDA Social Media

Past: Closed Innovation Future: Open Innovation

Page 30: FDA Social Media

Misconceptions about theFDA & Social Media

Page 31: FDA Social Media

Misconception #1

Social Media = Digital Advertising

/

Page 32: FDA Social Media

Misconception #2

Social Media Content = Social Media Platform

/

X X

X X

Page 33: FDA Social Media

Misconception #3

Having a Presence in Social Media = Being Social

/

Page 34: FDA Social Media

Dialogue is at the heart of social media

Page 35: FDA Social Media

Misconception #4

All Adverse Events Must Be Reported

Page 36: FDA Social Media

FDA Criteria for AE Reporting

1.An identifiable patient.2.An identifiable person reporting the

event.3.A suspect drug or biological

product.4.An adverse experience or fatal

outcome suspected to be due to the suspect drug or biologic.

Page 37: FDA Social Media

5

500: 1Among 500 messages

analyzed, one message incorporated all four AE

reporting criteria

2008 Study:Listening to Consumer in a highly regulated environment

Page 38: FDA Social Media

# reported = 0

Page 39: FDA Social Media

Misconception #6

The FDA is going to provide clear guidelines for every possible

aspect of social media.

Page 40: FDA Social Media

3 Future Trends and What This means for Canada Pharma

Page 42: FDA Social Media

Trend #1:Non-branded Corporate Communications will become the most dominant form of Pharma Social Media

Page 43: FDA Social Media

Trend #2: Brand as publisher. Beyond CSR content shift toward non –branded education content

Page 44: FDA Social Media

Trend #3: The New DTC = Direct to Customer

Page 45: FDA Social Media

DTC: Direct to Customer

•Cost of patient non-compliance = $30 Billion•Companies will focus on adherence as much as acquisition• High produced educational videos vs. hard to read drug information text• Both public facing videos (disease content) and password protected (product direct content) video. May not be consider DTC.• Same energy and production values in pre-purchase should be applied to post purchase

Page 46: FDA Social Media

• Focus on Global Corporation Communications• Brand as publisher: Educational non-branded content• The New DTC = Direct to Customer

Page 47: FDA Social Media
Page 48: FDA Social Media
Page 49: FDA Social Media

Thank You

Page 50: FDA Social Media

Brad B McCormick

Global Digital Director

Porter Novelli

[email protected]

646 662 6297

@darbtx